Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Published Date: 02 Jun 2026

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Read Full News

Latest News

HTTP error: 503

News All Time

HTTP error: 503HTTP error: 503 HTTP error: 503 HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alternative breast imaging techniques beyond mammography.

2.

Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars

3.

Capivasertib Wins Metastatic Prostate Cancer Approval

4.

Fixed-Duration Combo Shows Promise for Relapsed MCL

5.

Q&A: Breast cancer facts that could save lives


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot